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Clinical and Economic Impact of Diabetes Mellitus on
Percutaneous and Surgical Treatment of Multivessel
Coronary Disease Patients
Insights From the Arterial Revascularization Therapy Study (ARTS) Trial
Alexandre Abizaid, MD, PhD; Marco A. Costa, MD, PhD; Marinella Centemero, MD;
Andrea S. Abizaid, MD; Victor M.G. Legrand, MD; Robert V. Limet, MD; Gerhard Schuler, MD;
Friedrich W. Mohr, MD; Wietze Lindeboom, MSc; Amanda G.M.R. Sousa, MD, PhD;
J. Eduardo Sousa, MD, PhD; Ben van Hout, PhD; Paul G. Hugenholtz, MD, PhD; Felix Unger, MD;
Patrick W. Serruys, MD, PhD; on behalf of the ARTS Investigators
Background—Our aims were to compare coronary artery bypass grafting (CABG) and stenting for the treatment of
diabetic patients with multivessel coronary disease enrolled in the Arterial Revascularization Therapy Study (ARTS)
trial and to determine the costs of these 2 treatment strategies.
Methods and Results—Patients (n51205) were randomly assigned to stent implantation (n5600; diabetic, 112) or CABG
(n5605; diabetic, 96). Costs per patient were calculated as the product of each patient’s use of resources and the
corresponding unit costs. Baseline characteristics were similar between the groups. At 1 year, diabetic patients treated
with stenting had the lowest event-free survival rate (63.4%) because of a higher incidence of repeat revascularization
compared with both diabetic patients treated with CABG (84.4%, P,0.001) and nondiabetic patients treated with stents
(76.2%, P50.04). Conversely, diabetic and nondiabetic patients experienced similar 1-year event-free survival rates
when treated with CABG (84.4% and 88.4%). The total 1-year costs for stenting and CABG in diabetic patients were
$12 855 and $16 585 (P,0.001) and in the nondiabetic groups, $10 164 for stenting and $13 082 for surgery.
Conclusions—Multivessel diabetic patients treated with stenting had a worse 1-year outcome than patients assigned to
CABG or nondiabetics treated with stenting. The strategy of stenting was less costly than CABG, however, regardless
of diabetic status. (Circulation. 2001;104:533-538.)
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Diabetes has been found to be an important risk factor forpoor outcome after percutaneous transluminal coronary
angioplasty (PTCA).1–6 Subgroup analysis of the Bypass
Angioplasty Revascularization Investigation (BARI) random-
ized trial demonstrated that diabetic patients with multivessel
coronary disease had worse long-term outcome when treated
with balloon angioplasty than with coronary artery bypass
graft surgery (CABG).7 These findings have been corrobo-
rated by the 8-year follow-up analysis of the Emory Angio-
plasty versus Surgery Trial (EAST).8
When interpreting the results from past studies,9,10 it is
important to realize that the introduction of intracoronary stents
and the routine use of arterial conduits for bypass surgery have
resulted in a remarkable improvement in outcomes after both
percutaneous and surgical revascularization.6,11–17
The Arterial Revascularization Therapy Study (ARTS) was
designed to compare CABG and stenting for the treatment of
patients with multivessel coronary disease.18 The aims of the
present study were to compare the results of CABG and
stented angioplasty in diabetic patients with multivessel
coronary disease enrolled in the ARTS trial and to determine
the cost of these 2 treatment strategies.
Methods
ARTS Trial Design
Between April 1997 and June 1998, 1205 patients were randomized
to either stent implantation (n5600) or CABG (n5605) at 67
participating centers worldwide. A detailed description of the ARTS
protocol has been reported previously.18 In brief, only patients
without previous angioplasty or CABG procedures were included.
Received January 29, 2001; revision received May 22, 2001; accepted May 24, 2001.
From the Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil (A.A., M.A.C., M.C., A.S.A., A.G.M.R.S., J.E.S.); Academisch Ziekenhuis
Rotterdam Dijkzigt (M.A.C., P.W.S.), Cardialysis BV (W.L.), Institute for Medical Technology Assessment (B.v.H.), and Erasmus University Rotterdam
(P.G.H.), Rotterdam, Netherlands; CHU Sart Tilman, Liege, Belgium (V.M.G.L., R.V.L.); Herzzentrum Leipzig, Germany (G.S., F.W.M.); and Klinik
für Herzchirurgie, Landeskliniken, Salzburg, Austria (F.U.).
Correspondence to Professor P.W. Serruys, MD, PhD, Interventional Cardiology Department, Heartcenter/Erasmus University Rotterdam, Thorax-
center, Bd-408, Dr Molewaterplein 40, 3015 GD, Rotterdam, Netherlands. E-mail serruys@card.azr.nl
© 2001 American Heart Association, Inc.
Circulation is available at http://www.circulationaha.org
533
The indications for revascularization were silent ischemia, stable or
unstable angina pectoris, and the presence of $2 de novo lesions
located in different major epicardial coronary arteries, potentially
amenable to stent implantation. Complementary conventional bal-
loon angioplasty was allowed for the treatment of vessels with a
reference diameter ,2.75 mm. Patients with left main stem stenosis,
impaired left ventricular function (left ventricular ejection fraction
,30%), previous cerebrovascular accident (CVA), myocardial in-
farction (MI) within the week preceding randomization, or severe
hepatic or renal disease and patients who needed concomitant major
surgery were not included in the study.
Stents were implanted according to current clinical practice, with
high-pressure postdilatation. Bypass surgery also followed current
standard techniques, preferably with the left internal mammary
artery for revascularization of the left anterior descending coronary
artery and cold potassium cardioplegia (crystalloid or blood) for
myocardial protection.
Data Analysis
Angiographic (anatomic) data, including the characteristics of each
lesion and target coronary segment, were adjudicated by an indepen-
dent core laboratory (Cardialysis BV). MI occurring within 7 days of
the procedures was defined as the appearance of a new Q wave and
cardiac enzymes .5 times the upper limit of normal or a ratio of
peak creatine kinase (CK)-MB/CK .0.1. To define an MI after 7
days, either ECG or enzymatic criteria were applied.
The Minnesota criteria code for pathological Q waves19 was used,
and the ECGs were analyzed by an independent core laboratory.
Every itemized clinical event, including death, MI, and any repeat
revascularization, as well as the combined major cardiac (death, MI,
and repeated revascularization) and cerebrovascular (stroke, tran-
sient ischemic attacks, and reversible ischemic neurological deficits)
events (MACCE) were counted from the date of randomization until
1-year follow-up. Clinical events were adjudicated by an indepen-
dent committee.
TABLE 1. Baseline Clinical Characteristics
Characteristics
Diabetes Nondiabetes
Stent
(n5112)
CABG
(n596) P
Stent
(n5488)
CABG
(n5509) P
Age, y 62.4 62.6 0.111 60.3 61 0.832
Male, % 73.2 68.8 0.479 77.9 77.4 0.861
Unstable angina, % 39.3 39.6 0.965 39.3 42.4 0.321
Silent ischemia, % 3.6 4.2 0.824 6.6 4.9 0.264
Previous MI, % 41.1 49 0.255 45.1 40.7 0.160
Hypertension, % 64.3 56.3 0.238 40.2 42.8 0.394
Hypercholesterolemia, % 55.4 49 0.785 58.6 59.3 0.816
Family history, % 41.4 32.6 0.192 38.6 43.7 0.103
Current smoking, % 20.5 16.7 0.476 29.6 27.6 0.484
Left ventricular ejection fraction, % 60.5 60.3 0.965 61 60.4 0.796
TABLE 2. Angiographic and Procedure-Related Factors
Variables
Diabetes Nondiabetes
Stent
(n5112)
CABG
(n596) P
Stent
(n5488)
CABG
(n5509) P
No. of segments diseased 3.061.3 2.961.1 0.554 2.861.0 2.861.0 1.0
Two vessels, % 62 64 0.774 69 64 0.321
Three vessels, % 38 36 0.877 30 35 0.571
Lesion type*
A/B1, % 30.4 35.8 0.438 32.9 38.6 0.285
B2/C, % 69.6 64.2 0.438 67.1 61.4 0.264
No. of segments treated 2.861.5 2.760.8 0.559 2.661.1 2.760.8 0.1
No. of stents implanted 3.061.5 2.761.2
No. of distal anastomoses 2.760.7 2.760.9
Target vessel
Left anterior descending, % 83 92 0.065 84 91 0.196
Right coronary artery, % 63 65 0.756 65 71 0.652
Left circumflex, % 62 78 0.058 55 67 0.214
Total stent length, mm 52.7625.6 46.4620.6
Maximal balloon pressure, atm 14.962.9 14.662.8
Abciximab, % 3.5 2.8
Left internal mammary artery, % 89.3 99.7
*According to the American College of Cardiology/American Heart Association classification.
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Cost Analysis
Costs were limited to the direct medical costs per patient, assessed
from a societal perspective. Costs per patient were calculated as the
product of each patient’s use of resources and the corresponding unit
costs (US dollars). Data on the use of resources comprised a
selection of so-called “big-ticket” items: hospital days, postoperative
intensive care, coronary care, nonintensive/noncoronary care unit,
and diagnostic and therapeutic procedures (eg, outpatient visits,
angiography, intra-aortic balloon pumping, rehabilitation, etc). In
addition, data were collected concerning medication and the items
(balloons, wires, catheters, stents) that were used during the revas-
cularization procedures as well as data concerning the duration of the
various procedures. All data were collected on the case report form,
but patients were also given a “passport” so that the corresponding
information could be recorded if they were treated at other hospitals.
Unit costs were estimated (before analysis of the data) on the basis
of detailed information from Dijkzigt Hospital, as reported earli-
er.14,20 The costs per procedure, excluding the costs of those items
that were specifically recorded, were estimated as the product of
(1) the duration of the procedure in minutes and (2) an estimate of the
costs per procedure-minute.
Study Population
All patients enrolled in the ARTS trial were eligible for the present
investigation. Patients were divided into 2 groups: diabetes (n5208)
and nondiabetes (n5997). The steering committee recommended
that all diabetic patients be treated with oral hypoglycemic agents or
insulin at study entry. Short-term (up to hospital discharge) and
1-year clinical outcomes of patients assigned to stent and CABG
were compared within each group. All patients gave written in-
formed consent.
Statistical Analysis
Statistical analysis was performed with SAS 6.12 software (SAS
Institute Inc). Continuous variables were expressed as mean6SD
and were compared by unpaired Student’s t test. Fisher’s exact test
was used for categorical variables. Binary outcome variables are
reported as frequencies and percentages and were compared in terms
of relative risk with 95% CIs calculated by the formula of Greenland
and Robins.21 Comparisons between stent and CABG were per-
formed within each group (diabetes and nondiabetes). Multivariate
logistic regression models were constructed by use of baseline
clinical and angiographic characteristics as well as procedure-related
factors to identify independent risk factors for MACCE at 1 year in
each randomized arm of the ARTS trial (stent or CABG). All
statistical tests were 2-tailed, and a value of P,0.05 was considered
significant.
Results
Baseline clinical and demographic characteristics as well as
angiographic and procedure-related variables were similar
between patients assigned to stent and CABG within each
study group (Tables 1 and 2).
Short-Term Clinical Outcome
Until hospital discharge, patients assigned to stent and CABG
had a similar incidence of combined clinical events (Table 3).
In the diabetes group, however, repeat revascularization was
carried out more often after stenting than after CABG (4.5%
versus 0%, P50.04), whereas CVAs occurred only in patients
treated with CABG (4.2% versus 0%, P50.04).
TABLE 4. One-Year Clinical Outcome
Diabetes Nondiabetes
Stent
(n5112)
CABG
(n596) P
Stent
(n5488)
CABG
(n5509) P
Death, n (%) 7 (6.3) 3 (3.1) 0.294 8 (1.6) 14 (2.8) 0.412
Cerebrovascular events, n (%) 2 (1.8) 6 (6.3) 0.096 7 (1.4) 6 (1.2) 0.722
MI, n (%) 7 (6.3) 3 (3.1) 0.294 25 (5.1) 21 (4.1) 0.453
Q-wave, n (%) 6 (5.4) 2 (2.1) 0.222 22 (4.5) 20 (3.9) 0.649
Repeat revascularization*
CABG, n (%) 9 (8.0) 0 ,0.001 19 (3.9) 3 (0.6) ,0.001
PTCA, n (%) 16 (14.3) 3 (3.1) ,0.001 57 (11.7) 15 (2.9) ,0.001
Event-free, n (%) 71 (63.4) 81 (84.4) ,0.001 372 (76.2) 450 (88.4) ,0.001
*P50.04 for diabetes (stent) versus nondiabetes (stent).
TABLE 3. Short-Term Outcome (Up to Discharge)
Diabetes Nondiabetes
Stent
(n5112)
CABG
(n596) P
Stent
(n5488)
CABG
(n5509) P
Death, n (%) 3 (2.7) 2 (2.1) 0.780 3 (0.6) 6 (1.2) 0.208
Cerebrovascular events, n (%) 0 4 (4.2) 0.041 3 (0.6) 3 (0.6) 0.848
MI, n (%) 3 (2.7) 3 (3.1) 0.848 11 (2.3) 17 (3.3) 0.097
Q-wave, n (%) 3 (2.7) 2 (2.1) 0.780 11 (2.3) 16 (3.1) 0.144
Repeat revascularization
CABG, n (%) 4 (3.6) 0 0.173 7 (1.4) 1 (0.2) 0.113
PTCA, n (%) 1 (0.9) 0 0.354 8 (1.6) 3 (0.6) 0.197
Event-free, n (%) 101 (90.2) 87 (90.6) 0.762 456 (93.4) 479 (94.1) 0.665
In-hospital stay, d 5.264.1 13.269.2 ,0.001 4.564.7 11.265.7 ,0.001
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One-Year Clinical Outcome
Patients assigned to stenting compared with CABG had a
higher incidence of combined MACCE, regardless of diabetic
status (Table 4). The incidence of death, CVA, and MI (or the
combination of all 3 items), however, was similar between
stent and CABG within each group (Table 4).The cause of
death in the diabetic patients assigned to stented angioplasty
was as follows: procedure-related complication (1 patient),
stent thrombosis (2 patients), sudden death (2 patients), MI
complicated by heart failure (1 patient), and noncardiac death
due to renal cancer (1 patient). In the CABG group, the causes
of death were periprocedural MI (2 patients) and sudden
death (1 patient).
Diabetic patients treated with stenting had the lowest
1-year event-free survival rate (Figure) because of a higher
incidence of repeat revascularization than both diabetic pa-
tients treated with CABG and nondiabetic patients (Table 4).
Conversely, diabetic and nondiabetic patients experienced
similar 1-year event-free survival rates when treated with
CABG (Figure).
Predictors of Late Clinical Outcome
Independent risk factors for late clinical outcome (MACCE)
in the stent and CABG arms of the ARTS population are
displayed in Table 5. Diabetes appeared to be a strong risk
factor for the occurrence of MACCE in the population
assigned to stenting but not in those assigned to CABG.
Costs
Table 6 presents the difference in costs after 1-year follow-
up. The initial costs were significantly higher in the patients
assigned to CABG versus stented angioplasty in both groups.
Part of the initial difference in costs was lost, however,
because of more repeat revascularizations at follow-up after
stenting in the nondiabetic patients. Interestingly, there was
no significant difference in follow-up costs between stent
versus CABG in the diabetes groups (Table 6). Expenses with
respect to rehospitalization (40 of 96 diabetic CABG patients
were readmitted) in the diabetes group were primarily due to
comorbid factors related to the presence of diabetes rather
than the additional cost of repeat revascularization. The main
causes of rehospitalization in the diabetic CABG group were
sternal infection (7 patients), CVA (6 patients), gastrointes-
tinal bleeding (3 patients), renal insufficiency (3 patients),
pulmonary embolism (2 patients), and heart failure (2 pa-
tients). At 1 year, the net difference in favor of the percuta-
neous treatment was $3730 in the diabetes and $2918 in the
nondiabetes groups, respectively.
Discussion
This study, which is a subanalysis of the ARTS trial,18 reveals
that in patients with diabetes mellitus and multivessel coro-
nary artery disease, surgical revascularization with routine
use of arterial bypass conduits provides a superior 1-year
clinical outcome compared with percutaneous treatment, even
when a strategy of stented angioplasty is applied.
In the present investigation, surgery carried a substantial
risk of CVA in the diabetic patients (Table 3). These patients
TABLE 5. Independent Correlates With One-Year MACCE
Stent (n5600) CABG (n5605)
P
Odds
Ratio P
Odds
Ratio
Diabetes mellitus 0.002 2.1
Maximal balloon pressure in LAD 0.002 0.95
No. of stents implanted in mid-RCA 0.004 1.43
Stenosis in distal RCA 0.02 4.53
No. of unsuccessful treated segments* 0.03 1.27
Elevated CK-MB 0.0001 1.73
Increasing age 0.002 1.06
Use of heparin 0.003 2.66
Abnormal hematocrit 0.01 2.56
Intra-aortic balloon pump 0.03 9.44
Anastomosis in distal RCA 0.04 0.4
LAD indicates left anterior descending coronary artery; RCA, right coronary artery.
*Successful treatment: ,50% diameter stenosis after balloon angioplasty or ,20% diameter
stenosis after stented angioplasty by visual assessment.
Kaplan-Meier event-free survival curves for death, cerebrovas-
cular events, MI, or any repeat revascularization of patients
assigned to stenting vs CABG according to diabetes status
(P,0.001 for stent vs CABG in both diabetes and nondiabetes
groups; P50.004 for diabetes/stent vs nondiabetes/stent; P5NS
for diabetes/CABG vs nondiabetes/CABG).
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appear to have a higher incidence of CVA (6.3%) than the
general population (2.4%) treated with CABG.22 Such find-
ings may highlight the importance of diabetes as an indepen-
dent risk factor for CVA after CABG, as reported
previously.23
The 5-year follow-up of the BARI7 trial, and more recently
the 8-year analysis of the EAST trial,8 have shown a higher
mortality rate in diabetic patients with multivessel disease
treated with PTCA compared with CABG. In the present
study, the incidence of 1-year mortality in the diabetic
patients assigned to stented PTCA was twice as high as in
those assigned to CABG (6.3% versus 3.1%; P5NS) (Table
4). Although this difference was not statistically significant, it
is possible that with longer follow-up and a larger sample
size, the difference in mortality rate could achieve statistical
significance. In this regard, it is worth noting that the
difference in mortality between the CABG- and PTCA-
treated patients with diabetes in the EAST trial was not
evident after 3 years.10 The hypothesis that late lesion
progression in nontreated coronary segments is an important
cause of mortality in diabetic patients with multivessel
coronary disease24,25 may explain the difference in results
observed with shorter-term (,3 years) versus longer-term
(.5 years) follow-up.
In diabetic patients, the difference in favor of CABG in
repeat revascularization was almost twice as great as in the
nondiabetic group (21.6% versus 12.4%, respectively). Fur-
thermore, diabetes was an independent risk factor for 1-year
MACCE in the stent arm but not in the CABG arm of the
ARTS trial. A possible explanation for these findings may be
that diabetes has been associated with both increased reste-
nosis26–28 and late vessel occlusion29 in stented vessels
because of either enhanced neointimal proliferation or vas-
cular thrombosis.30,31
Considering that both thrombosis and restenosis may be
implicated in the high incidence of repeat revascularization in
diabetic patients treated percutaneously, modern adjunctive
therapies have been proposed to improve the outcome of this
high-risk population. In the EPISTENT trial, the target-vessel
revascularization rate of diabetic patients who received a
stent plus abciximab was approximately half the rate of
patients who received a stent plus placebo.32 It is also
encouraging to note that intravascular radiation therapy has
been shown to be effective in the treatment of in-stent
restenosis in both diabetic and nondiabetic patients.33 Finally,
stents coated with drugs such as sirolimus are showing very
promising results, with essentially no late intimal hyperplasia
in either diabetic or nondiabetic patients.34 These recent
encouraging reports may further fuel the debate on the most
effective strategy for the treatment of these high-risk patient
subsets.
Because of the economic constraints of modern society,
physicians also need to consider the cost of each strategy
when counseling the diabetic patient with multivessel coro-
nary disease.35 A strategy of stented angioplasty was less
costly than CABG in both diabetic and nondiabetic patients
after 1-year follow-up (Table 6). Although CABG resulted in
a 21.6% lower rate of repeat intervention at 1 year, the
rehospitalization rates were higher in the diabetic patients
assigned to surgery because of non-MACCE complications,
such as sternal infection, renal insufficiency, heart failure,
pulmonary embolism, and gastrointestinal bleeding.
Because technologies continuously evolve, this balance
between costs and the outcome achieved is likely to change.
Limitations
Diabetes was not the original focus of the ARTS trial. It is the
first prospective, randomized trial, however, comparing
stented angioplasty and CABG for the treatment of multives-
sel coronary disease by contemporary techniques (more
complete revascularization in the percutaneous arm with
stents and use of arterial conduits in .90% of the cases in the
CABG group). This substudy reports on the differences in
costs between the patient cohorts but is underpowered to truly
assess “cost-effectiveness,” ie, whether the added costs of
CABG in diabetics was economically justifiable. We believe,
however, that these data will serve as an important frame of
reference for clinicians until the results of a large, randomized
trial in diabetics can provide a more definitive answer to this
problem.
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